FINWIRES · TerminalLIVE
FINWIRES

Walmart to Post Strong Q1, Extending Retail Lead on Sales Growth, UBS Says

By

Walmart (WMT) is expected to report a strong Q1, with US sales, profit growth, international strength, online gains, pricing power and newer revenue streams supporting further upside, UBS said in a note Wednesday.

UBS said Walmart US comparable sales are expected to rise about 4.5%, helped by more than 25% growth in online sales, though weaker pharmacy trends may weigh on store sales, while Walmart US and international operating income could come in at least near the high end of the company's 6% to 8% growth range.

The investment firm expects Sam's Club earnings to be roughly flat from a year earlier because the business faces a tougher comparison, though Walmart may raise its full-year earnings outlook if Q1 earnings come in ahead of expectations, though higher fuel costs remain a risk.

Higher gas prices could pressure costs, but Walmart may still gain market share as shoppers look for lower prices, according to the note.

UBS kept its buy rating and $147 price target for Walmart.

Price: $132.03, Change: $+0.56, Percent Change: +0.43%

Related Articles

Australia

Argus Lowers McDonald's Price Target to $320 From $380

McDonald's (MCD) has an average rating of overweight and mean price target of $332.47, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $275.01, Change: $-0.69, Percent Change: -0.25%

$MCD
Australia

Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint

(Updates with latest stock price movement in the headline and first paragraph, Q1 earnings in the second through sixth paragraphs.)Regenxbio's (RGNX) shares were down about 36% in Thursday afternoon trading after its Q1 swung to a loss and revenue declined.The company reported a Q1 net loss Thursday of $1.72 per diluted share, swinging from earnings of $0.12 a year earlier.Analysts polled by FactSet expected a loss of $1.34.Revenue for the quarter ended March 31 fell to $6.4 million from $89.0 million a year earlier.Analysts surveyed by FactSet expected $25.8 million.The company expects its cash, cash equivalents and marketable securities of $150.5 million as of March 31 to fund its operations into early 2027.Separately, the company said Thursday its investigational gene therapy RGX-202 met the primary endpoint in the pivotal phase III portion of the Affinity Duchenne trial for Duchenne Muscular Dystrophy.The company said 93% of patients achieved over 10% microdystrophin expression at week 12.Regenxbio said it is preparing to pursue accelerated approval based on the data and is targeting a potential commercial launch in 2027.Price: $6.47, Change: $-3.57, Percent Change: -35.56%

$RGNX
Australia

Altria Maintains Quarterly Dividend at $1.06 per Share, Payable July 10 to Holders of Record June 15

Price: $72.02, Change: $+0.48, Percent Change: +0.67%

$MO